Previous 10 | Next 10 |
home / stock / flhlf / flhlf news
FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT Canada NewsWire Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC , July 13, 2022 /CNW/ - Filament Hea...
FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , July 12, 2022 /CNW/ - Filament He...
Filament Health ( OTC:FLHLF ) on Thursday said it had started dosing in its FDA-approved trial to evaluate its psychedelic drug candidates. FLHLF said the phase 1 trial would be the first to administer psilocin and psilocybin directly derived from magic mushrooms, instead ...
FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL Canada NewsWire The trial, conducted at UCSF's TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer psilocin, the active fo...
The trial, conducted at UCSF’s TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer psilocin, the active form of psilocybin Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7Q...
FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , July 6, 2022 /CNW/ - Filament Health Corp. ( OTCQB: FLHLF ...
FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000 Canada NewsWire Financing driven by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC , ...
FILAMENT HEALTH ANNOUNCES ANNUAL GENERAL MEETING VOTING RESULTS Canada NewsWire VANCOUVER, BC , June 28, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural...
FILAMENT HEALTH ANNOUNCES PATIENT DOSING THROUGH HEALTH CANADA SPECIAL ACCESS PROGRAM Canada NewsWire VANCOUVER, BC , June 16, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage n...
FILAMENT HEALTH CULTIVATES 70TH PSYCHEDELIC MUSHROOM VARIETY AND ANNOUNCES ANNUAL GENERAL MEETING Canada NewsWire VANCOUVER, BC , June 10, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clin...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...